MedTrace Logo

Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers

NCT03463837 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-06-21

No results posted yet for this study

Summary

The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using three JUUL 5% ENDS compared to smoking usual brands of combustible cigarettes and stopping smoking.

Conditions

  • Nicotine Dependence, Other Tobacco Product
  • Tobacco Use
  • Smoking, Tobacco

Interventions

OTHER

Treatment with JUUL 5%, Virginia Tobacco

JUUL 5%, ENDS for 5-days in confinement

OTHER

Treatment with JUUL 5%, Cool Mint, ENDS

JUUL 5%, ENDS for 5-days in confinement

OTHER

Treatment with JUUL 5%, Mango, ENDS

JUUL 5%, ENDS for 5-days in confinement

OTHER

JUUL 5%, Creme Bruele, ENDS

JUUL 5%, ENDS for 5-days in confinement

OTHER

Combustible cigarette

Exclusive use of combustible cigarette for 5 days in confinement.

OTHER

Smoking Cessation

No smoking for 5-days in confinement.

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Juul Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Philip Mathew, M.D. · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-04
Primary Completion
2018-07-27
Completion
2018-08-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463837 on ClinicalTrials.gov